
ExstoBio provides precision cannabinoid healthcare to help patients manage chronic conditions with a data-driven, science-first approach. The platform combines clinical research expertise from top scientists with artificial intelligence and patient-reported outcomes to personalize cannabinoid treatment recommendations and track outcomes. It operates as a consumer health platform with clinical and research-facing capabilities, serving patients alongside clinicians and researchers. ExstoBio focuses on cannabis-as-medicine applications for chronic disease and emphasizes evidence generation and measurable patient outcomes.

ExstoBio provides precision cannabinoid healthcare to help patients manage chronic conditions with a data-driven, science-first approach. The platform combines clinical research expertise from top scientists with artificial intelligence and patient-reported outcomes to personalize cannabinoid treatment recommendations and track outcomes. It operates as a consumer health platform with clinical and research-facing capabilities, serving patients alongside clinicians and researchers. ExstoBio focuses on cannabis-as-medicine applications for chronic disease and emphasizes evidence generation and measurable patient outcomes.
What they do: Personalized medical cannabis platform delivering precision cannabinoid therapeutics using a science-based, data-driven approach.
Headquarters: Chapel Hill, North Carolina, United States
Funding signal: Grant funding including IdeaFest (Apr 21, 2023) and NC IDEA (Oct 2023)
Founders: David Lee, Ph.D.; Juan Carlos Pacheco
Team size (public listing): Listed as 1 employee (sources vary)
Medical cannabis / precision cannabinoid therapeutics for chronic conditions
Biotechnology
Listed as a grant round on Apr 21, 2023; amount not disclosed.
Listed as a grant entry (Oct 2023) with amount shown as N/A.
“Received grant funding from IdeaFest and NC IDEA”